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Abstract
Background: Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested 
in early phase studies of mood disorders. Objective: The identification of biomarkers could help develop personalized psychiatric treatments that may impact 
public health. Methods: These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches 
including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results: To date, early 
phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also 
sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of 
Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified 
changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with 
treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion: These approaches may ultimately provide clues into the neurobiology 
of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.
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Introduction
In 2012, the United States Food and Drug Administration (FDA) 
approved 39 new drugs; however, none of these were approved for 
psychiatric indications1. While new and mechanistically distinct 
agents were approved for oncology and other medical subspecialties, 
negative results in early Phase II psychiatric research studies continue 
to limit the development and approval of successful compounds, 
despite the fact that psychiatric disorders have a greater morbidity 
burden than cardiovascular disease or cancer2. Several factors have 
contributed to the proverbial drying of the medication pipeline, 
including high study attrition rates, long lead-time development, the 
heterogeneity of psychiatric disorders, and our lack of a mechanistic 
understanding of their underpinnings3. Thus, new and improved 
agents are urgently needed to treat psychiatric disorders; this, in 
turn, reinforces the need for additional research and investment for 
central nervous system (CNS) drug development. Our laboratory 
and others have focused on identifying specific biomarkers to tackle 
these challenges. Although larger collaborative efforts with industry 
will ultimately be required to validate these efforts, the identification 
and development of biomarkers by academia may kick-start drug 
development in psychiatric disorders. 
Background
The NIH Biomarkers Definitions Working Group defines a “bio-
marker” as “a characteristic that is objectively measured and evalu-
ated as an indicator of normal biological processes, pathogenic pro-
cesses, or pharmacological responses to a therapeutic intervention4”. 
Researchers believe biomarkers to be particularly useful in three 
major areas: 1) drug development, 2) diagnosis and/or prognosis, 
and 3) patient management5. All three of these domains are directly 
involved in the personalized treatment of patients. Indeed, surrogate 
markers can hasten drug discovery by assessing early efficacy and 
reducing overall clinical trial duration and costs6. In psychiatry, 
and more specifically, in mood disorders, the search for potential 
biomarkers has encompassed several areas of research, including 
clinical/demographic factors, genetic/molecular factors, quantita-
tive electroencephalography (qEEG), neuroimaging, and loudness 
dependence of auditory-evoked potentials7,8. As our burgeoning 
use of high-throughput “multi-omics” increases9 (e.g., genomics, 
lipidomics, metabolomics, proteomics, and epigenetics), we will 
surely gain deeper insight into the pathophysiological mechanisms 
that underlie mood disorders. 
In 2004, the FDA issued a “Critical Path Initiative” designed to 
increase the efficiency of product development and safety testing 
industry-wide. In 2005, the FDA also provided guidance for a vo-
luntary submission path for initial, exploratory pharmacogenomic re-
search data to improve biomarker-driven drug development. Notably, 
depression was considered a key therapeutic area for future studies 
and investment10. New techniques and disciplines in translational 
psychiatry also support the role of new therapeutic strategies. More 
recently, the model proposed by the National Institute of Mental 
Health (NIMH) new Research Domain Criteria (RDoC) reinforced 
the need to identify neural circuits and related biomarkers associated 
with psychiatric disorders, and detect early manifestations associ-
ated with increased risk for illness that may appear before the onset 
of cognitive and behavioral changes. The RDoC model also aims to 
define approaches centered on individual responses, as well as foster 
the augmented use of effective psychosocial approaches. This, in turn, 
will help reduce sample size and allow for researchers to generate 
more meaningful early proof-of-concept clinical trials and may help 
identify therapeutically relevant biomarkers. 
Biomarkers: qualification and exploration 
Validated biomarkers target objective measures of pathogenic or 
pharmacological effects. Notably, studies have found that such bio-
markers reduce the risk of type I (false-positive) and type II (false-
negative) errors11. The process of biomarker qualification includes 
four broad concepts: exploration, demonstration, characterization, 
and surrogacy12. Wagner further defined proximal biomarkers as 
those identified in earlier phases of study – that is, those evaluating 
target engagement – and distal biomarkers as those characterized 
in later stages of investigation, typically in an illness pathway com-
ponent12. On a separate but related note, the FDA has a Biomarkers 
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Qualification Process (BQP) for biomarkers that are anticipated to 
affect regulatory review, drug development and, ultimately, patient 
care13.
With regard to complex psychiatric disorders, current biomarker 
research has largely been circumscribed to the investigational phase; 
as a result, such work functions solely in the domains of research and 
development. Below, we review some of the most salient biomarker 
findings in psychiatric research.
Novel proof-of-concept studies14 from our laboratory have used 
clinical phenotypic data, neurophysiologic measures, peripheral and 
genetic markers and functional neuroimaging to not only help predict 
treatment outcomes with rapid-acting new antidepressants such as 
ketamine and scopolamine (though it should be noted that both are 
old pharmacological agents), but also to help clarify the underlying 
neural correlates of their well-described rapid antidepressant actions. 
For instance, elevated pretreatment/baseline anterior cingulate corti-
cal activity in a fearful face paradigm predicted rapid antidepressant 
response to ketamine15. This result is consistent with previous findings 
that baseline anterior cingulate cortex (ACC) metabolism predicts 
antidepressant response to standard antidepressants16. The ketamine 
studies not only replicated previous findings but also expanded them 
to a novel non-monoaminergic drug whose antidepressant effects 
took place within a few hours. These findings strengthen the existing 
literature implicating a key role for ACC activity as a predictor for 
rapid antidepressant response17.
Another important finding is that of increased mammalian target 
of rapamycin (mTOR) phosphorylation in peripheral mononuclear 
cell protein after ketamine treatment18. These results concur with pre-
vious findings of rapid mTOR phosphorylation in the rat prefrontal 
cortex after low-dose ketamine in animal models of depression19. 
Because mTOR phosphorylation and associated signaling cascades 
have been involved in neoplastic processes and peripheral markers 
of mTOR activity (e.g., S6 kinase 1 (S6K1) inhibition)20, collecting 
such molecular profile data could offer insights into a hypothetical 
model to test other mTOR-active compounds for rapid antidepressant 
effects. Similarly, gathering data from patients at baseline could help 
identify potential responders before the drug (in this instance, ket-
amine) is even administered. While an a priori stratification approach 
has not been extensively performed in neuropsychiatric research, it 
is a rational conceptual framework for additional biomarker research 
in this field. One notable example is that the OPRM1A118G single 
nucleotide polymorphism (SNP) predicted antidepressant response 
to the opioid receptor antagonist naltrexone in alcohol use disorders21. 
In addition to the benefits associated with identifying potential 
relevant therapeutic targets, early patient stratification could also 
lead to improved preclinical-to-clinical translation. With regard to 
major mood disorders, patients enrolled in a typical clinical trial 
can appear behaviorally similar (for instance, experiencing a major 
depressive disorder), but have different diagnoses (for instance, bi-
polar disorder vs MDD). In addition, the etiology of even the same 
mood disorder may differ from patient to patient, as may key genetic 
variables, consistent with the RDoC model (e.g., genes, molecules, 
cells, neural circuits, neurophysiology). As a result, only a subset of 
patients may respond to a specific molecular target. Initial patient 
stratification has been tested in medical specialties such as oncol-
ogy; for instance, HER2 monoclonal antibody trastuzumab therapy 
in breast cancer tumors22. Cetuximab in epidermal growth factor 
receptor-overexpressing KRAS wild-type metastatic colorectal cancer 
used a similar approach23. Comparable methods have also been used 
to evaluate treatments for autoimmune diseases24,25. 
Other advantages of patient stratification/enrichment include the 
improved design of treatment protocols; when used in early drug de-
velopment, such protocols could study biomarkers at multiple levels 
(Figure 1). Also, the use of “efficacy-stratifying biomarkers14” could 
influence patient data at the molecular level before initial treatment, 
thereby enhancing power and, by reducing heterogeneity, limiting 
the need for larger samples; a good example would be family history 
of alcohol use disorders in first-degree relatives of individuals with 
either treatment-resistant MDD26 or bipolar depression27. Such a 
translational model28 in mood disorders may overcome heterogeneity 
challenges by excluding individuals at high risk of minimal response 
to a given intervention. Relatedly, collecting large databases of bio-
logical signatures/profiles would help identify and stratify targets for 
specific treatment approaches. This integrative method (Figure 1) 
could then be applied to other key agents to not only discover new 
therapeutics, but detect novel molecular targets and/or pathways that 
contribute to mood disorders.
Diagnostic and prognostic biomarkers
The development of diagnostic biomarkers for psychiatric disorders is 
a significant challenge, particularly because psychiatric disorders are 
typically characterized based on clinical observations of behavioral 
changes. However, the development of neurobiologically-informed 
diagnostic biomarkers represents a key area for further investigation 
in psychiatric research. Specifically, identifying diagnostic biomar-
kers is not based on current descriptive (and, as some have argued, 
theoretical) or categorical frameworks but, instead, is based on 
alternative dimensional concepts of mental disorders, such as the 
psychiatric framework established by the RDoC29. Furthermore, 
while initial studies have been conducted with multi-assay serum-
based diagnostic tests for MDD30, multimodal biomarker panels 
of pharmacologic and/or safety/toxicity profiles may ultimately 
represent a more valuable tool for both psychiatric research and, 
subsequently, clinical practice.
In addition, identifying predictive biomarkers in mood disorders 
using a “systems biology”-based approach that collects and integrates 
several hierarchical levels or domains31 is a promising tool for future 
research. This integrative approach – which can include molecular 
data, structural and functional neuroimaging, and clinical corre-
lates – contrasts with paradigms established by previous scientific 
discoveries. For example, both glial and synaptic dysfunction have 
been implicated in the pathophysiology of mood disorders32; how-
ever, it is unlikely that they could be considered a sole causal factor. 
Rather, the dynamic interplay between neuronal and non-neuronal 
biological mechanisms at the genetic, molecular, or cellular level may 
generate the dysfunctional neural circuitry and decreased cellular 
resilience associated with mood disorders33. Supporting this model, 
the calcium channel, voltage-dependent, L type alpha 1C subunit gene 
(CACNA1C) was found to be involved in several psychiatric disor-
ders34, though it remains unclear whether the associated molecular 
changes were a cause or an effect of the dysfunction in upstream or 
downstream domains, or what their key functional targets impact-
ing behavioral and cognitive modulation might be. In this context, 
a “systems biology” method has been effectively exploited in oncol-
ogy and other medical areas, where heterogeneity is usually present 
in diseases subtypes. This innovative “systems biology” approach 
remains untested for the study of neuropsychiatric diseases. Devoted 
interdisciplinary approaches will be required in order to accumulate 
sufficient quantitative data and develop new computational neurosci-
ence models and other innovative approaches before its full potential 
can be assessed35,36.
Limitations and future directions
Despite the great potential associated with developing clinically useful 
biomarkers in personalized medicine, and the excitement over this 
burgeoning field, fewer than 100/150,000 (0.06%) publications in 
the biomedical biomarker literature have been endorsed for routine 
clinical practice37. Questions regarding standardization of specimen 
collection/storage, matching control and disease samples (methods 
and size), and replication difficulties continue to limit the develop-
ment of potential translational findings into clinical practice37. In 
addition, close, careful follow-up with statistical and computational 
specialists, as well as data sharing networks and agreements, will 
be needed to draw definitive conclusions regarding biomarker re-
search in large datasets. In this context, imaging initiatives such as 
the International Neuroinformatics Coordinating Facility (INCF) 
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and their computing platforms (e.g., the NeuroDebian project) may 
allow for more efficient collaboration between academia, govern-
ment, and private initiatives38. These types of collaboration focus on 
promoting collaborative networks instead of the more typical isolated 
investigator-driven approach37. 
In the current “translational” era, all knowledge tends to be 
merged; multiple efforts work to reach a broad common goal: the 
progress of science. Because of the current limitations of diagnostic 
and treatment specificity, however, it is unlikely that any currently 
identified individual biomarker will substantially impact neuropsy-
chiatric research or care. Also, the development of biomarkers in a 
cost-effective manner will be challenging39, particularly because it 
will require new insights into systems biology and the development 
of other bioinformatics approaches40. Relatedly, it will be crucial 
to address the heterogeneity of descriptive diagnoses and evaluate 
neurobiologically-defined subgroups for maximal efficacy, particu-
larly because fewer drugs have been approved for neuropsychiatric 
indications in the last few years. Other challenges that will need to 
be addressed include the development of new diagnostic tools and 
scoring systems for quantitative biomarkers, and the development of 
clinical predictors of response and surrogate outcomes. With regard 
to bipolar disorder in particular, several courses of action might be 
taken to improve the success rates of clinical research while saving 
both time and money, for instance, conducting small proof-of-
concept Phase 1 trials of novel agents in surrogate populations (e.g. 
subjects with hyperthymia instead of bipolar disorder), or using 
pharmacological agents able to mimic some of the disease features in 
healthy volunteers. It is equally important to design clinical trials that 
can estimate the chances of success in initial clinical development. 
As discussed above, the focus in drug development has recently 
changed from hypothesis-driven studies to hypothesis-generating 
experiments using the new “-omics” generation of platforms and 
techniques. Though these technologies allow for unprecedented ex-
ploration of the mechanisms of action underlying various disorders, 
their results are much broader and can thus be difficult to interpret. 
For instance, 80% of the 25,000 human genes have some effect on the 
brain. Thus, hypothesis-generating approaches may even increase the 
level of intricacy associated with such studies due to their inability 
to “sift the wheat from the chaff ”.
Finally, there is also a serious need to “post-translate” results from 
proof-of-concept clinical research into medical care41. Such “transla-
tion” is imperative before scientific discoveries can be transformed 
from preclinical research into clinical applications, thus closing the gap 
between drug discovery in preclinical models and drug development in 
humans. Using new technologies to conduct close, careful identifica-
tion of new biomarkers – those associated with clinical relevance or 
prediction of pharmacological response to a particular treatment – will 
ensure more accurate individual treatment for those who need it most. 
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Dear Editor
Anorexia nervosa (AN) is an eating disorder whose therapeutic 
interventions usually produce unsatisfactory results. This disorder 
is characterized by high rates of relapse, tendency to chronicity, 
high morbidity and mortality1. Low motivation is a central issue 
that hinders AN treatment1. Interpersonal relationships seem to be 
crucial in AN and may play a role in this sense as well. We propose 
that specific patterns of interpersonal interactions can arise when 
professionals are dealing with AN subjects and that this peculiar 
rapport is not only a characteristic of the disorder in question, but 
could also be a part of what perpetuates and aggravates the problem. 
Those who interact with AN patients can refer feelings of help-
lessness, fear, anxiety and hopelessness2, pointing to a possible degree 
of aversivity in these relationships. This fact may be aggravated by the 
slow improvement typical of AN, which can be frustrating and, as a 
result of this, professionals can adopt a strong and directive attitude 
toward the patients trying to reach better outcomes in the treatment. 
In fact, a coercive attitude in AN can generate relatively quick results3, 
what can provide a transient attenuation of professional’s discom-
fort. This may have reinforcing effects over the controlling attitude, 
making it more likely to occur in future similar occasions. In other 
words, too much directivity appears to relief professional’s distress 
and, therefore, negatively reinforce coercive posture, but it may also 
have adverse consequences to the patient’s treatment4.
Fallouts are noticed as a remarkably paternalistic approach – 
seen, for example, in procedures such as involuntary hospitalization 
not based on scientific guideless or arbitrary tube feeding – tends to 
increase the already high resistance in these patients5. An intimidat-
ing posture also can punish potentially unpleasant statements made 
by the patient, possibly suppressing genuine reports and predisposing 
to false descriptions of improvement. Coercion-generated improve-
ments may be volatile and fragile and even unfavorable in the long 
term. For instance, forced hospitalizations decrease the voluntary 
search of treatment3, which is a major issue since the motivation to 
change is an important element for therapeutic success1. 
A healthy rapport seems to have an important role in reaching 
a favorable outcome in treatments since a mutual and reliable alli-
ance in AN increases the chance of a continuous and more effective 
approach4. However, according to Darcy et al.6 the therapist-patient 
alliance is yet relatively under-researched especially when studied 
from the professional perspective and there is a deficiency of men-
tal health professional’s continued training on the use of rational 
paternalistic techniques3.
In short, some evidence suggests that a directive posture is more 
common in AN compared to other mental disorders and may have 
unfavorable effects over its treatment. It seems to be important to 
establish a positive therapeutic alliance to optimize motivation in 
this disorder. Prioritize cooperation in AN apparently can shifts 
the focus from control to an efficient therapeutic bond. Further 
research on the professional-patient relationship in AN cases is 
needed in other to elucidated this point and enhance the success 
of interventions.
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